Hematology and Oncology

The Skin Cancer Institute at the University of Arizona Cancer Center Presents the Sixth Annual Melanoma Walk, Nov. 7

The Skin Cancer Institute at the University of Arizona Cancer Center will present the sixth annual Melanoma Walk on Saturday, Nov. 7, from 2 to 6 p.m., at the University of Arizona Cancer Center – North Campus, 3838 N. Campbell Ave., Tucson. The event opens at 2 p.m., and the walk starts at 4 p.m. The goal for Melanoma Walk 2015 is to raise $60,000 to fight melanoma.

Dr. Daniel Persky Named Associate Director of Clinical Investigations at UA Cancer Center

Dr. Daniel PerskyDaniel Persky, MD, a leading physician-scientist in the field of lymphoma translational research, has been named associate director of clinical investigations and director, Clinical Trials Office (CTO), at the University of Arizona Cancer Center. Dr. Persky will work closely with UA Cancer Center leadership to enhance clinical and translational research efforts.

UA Skin Cancer Expert Available to Speak on Melanoma Diagnosis, Treatment and Survival

[Lee D. Cranmer, MD, PhD]

Skin cancer is the most common form of cancer in the United States, with an estimated 3.5 million new cases diagnosed each year — more than all other cancers combined. Former President Jimmy Carter’s melanoma diagnosis, resonates in Arizona, where skin cancer rates rank among the highest in the world.

There are two categories of skin cancer, nonmelanoma skin cancer and melanoma. Nationally, one in five Americans will get skin cancer in their lifetime. The American Cancer Society has indicated that Arizona sees approximately 1,400 new cases of melanoma each year.

Umbreen Arshad Rozell, MD

Degrees: 
BS in Biological sciences with a minior in English, University of California, Davis

Board Certifications: 
American Board of Internal Medicine
American Board of Internal Medicine, Oncology
American Board of Internal Medicine, Hematology

Residency:
Internal Medicine, SUNY Upsate 
 

Abhijeet Kumar, MD

Profession Interests:
Immunotherapy and resistance to immune checkpoint inhibition in lymphoid malignancies, modalities to overcome late relapses in patients with localized DLBCL, clinical trials using combination of aurora kinase inhibition and BTK or downstream signaling inhibition as an modality for relapsed refractory double hit double protein or ABC subtype DLBCL ; Mechanisms Resistance to immune checkpoint inhibition in  sarcoma.

Pages

Subscribe to RSS - Hematology and Oncology